1256 related articles for article (PubMed ID: 19779718)
21. A folate receptor-targeted liposomal formulation for paclitaxel.
Wu J; Liu Q; Lee RJ
Int J Pharm; 2006 Jun; 316(1-2):148-53. PubMed ID: 16564654
[TBL] [Abstract][Full Text] [Related]
22. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
Allen TM; Mumbengegwi DR; Charrois GJ
Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
[TBL] [Abstract][Full Text] [Related]
23. Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity.
Shmeeda H; Amitay Y; Tzemach D; Gorin J; Gabizon A
J Control Release; 2013 May; 167(3):265-75. PubMed ID: 23419948
[TBL] [Abstract][Full Text] [Related]
24. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent.
Sochanik A; Mitrus I; Smolarczyk R; Cichoń T; Snietura M; Czaja M; Szala S
Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):235-45. PubMed ID: 20383751
[TBL] [Abstract][Full Text] [Related]
25. Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes.
Malhi SS; Budhiraja A; Arora S; Chaudhari KR; Nepali K; Kumar R; Sohi H; Murthy RS
Int J Pharm; 2012 Aug; 432(1-2):63-74. PubMed ID: 22531856
[TBL] [Abstract][Full Text] [Related]
26. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
Yoshizawa T; Hattori Y; Hakoshima M; Koga K; Maitani Y
Eur J Pharm Biopharm; 2008 Nov; 70(3):718-25. PubMed ID: 18647651
[TBL] [Abstract][Full Text] [Related]
27. Targeted magnetic liposomes loaded with doxorubicin.
Pradhan P; Banerjee R; Bahadur D; Koch C; Mykhaylyk O; Plank C
Methods Mol Biol; 2010; 605():279-93. PubMed ID: 20072888
[TBL] [Abstract][Full Text] [Related]
28. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
29. Effect of polyethylene glycol linker chain length of folate-linked microemulsions loading aclacinomycin A on targeting ability and antitumor effect in vitro and in vivo.
Shiokawa T; Hattori Y; Kawano K; Ohguchi Y; Kawakami H; Toma K; Maitani Y
Clin Cancer Res; 2005 Mar; 11(5):2018-25. PubMed ID: 15756028
[TBL] [Abstract][Full Text] [Related]
30. Relevance of folic acid/polymer ratio in targeted PEG-epirubicin conjugates.
Canal F; Vicent MJ; Pasut G; Schiavon O
J Control Release; 2010 Sep; 146(3):388-99. PubMed ID: 20621587
[TBL] [Abstract][Full Text] [Related]
31. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo.
Leamon CP; Cooper SR; Hardee GE
Bioconjug Chem; 2003; 14(4):738-47. PubMed ID: 12862426
[TBL] [Abstract][Full Text] [Related]
32. Folate receptor targeted delivery of liposomal daunorubicin into tumor cells.
Ni S; Stephenson SM; Lee RJ
Anticancer Res; 2002; 22(4):2131-5. PubMed ID: 12174894
[TBL] [Abstract][Full Text] [Related]
33. Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy.
Stephenson SM; Yang W; Stevens PJ; Tjarks W; Barth RF; Lee RJ
Anticancer Res; 2003; 23(4):3341-5. PubMed ID: 12926073
[TBL] [Abstract][Full Text] [Related]
34. Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells.
Lu Y; Wu J; Wu J; Gonit M; Yang X; Lee A; Xiang G; Li H; Liu S; Marcucci G; Ratnam M; Lee RJ
Mol Pharm; 2007; 4(5):707-12. PubMed ID: 17708654
[TBL] [Abstract][Full Text] [Related]
35. Tumour-selective drug delivery via folate receptor-targeted liposomes.
Pan X; Lee RJ
Expert Opin Drug Deliv; 2004 Nov; 1(1):7-17. PubMed ID: 16296717
[TBL] [Abstract][Full Text] [Related]
36. Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors.
Müller C; Schubiger PA; Schibli R
Nucl Med Biol; 2007 Aug; 34(6):595-601. PubMed ID: 17707798
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effect of folate-targeted liposomal doxorubicin in KB tumor-bearing mice after intravenous administration.
Riviere K; Huang Z; Jerger K; Macaraeg N; Szoka FC
J Drug Target; 2011 Jan; 19(1):14-24. PubMed ID: 20353291
[TBL] [Abstract][Full Text] [Related]
38. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
Hong RL; Tseng YL
Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
[TBL] [Abstract][Full Text] [Related]
39. Tumor detection using folate receptor-targeted imaging agents.
Sega EI; Low PS
Cancer Metastasis Rev; 2008 Dec; 27(4):655-64. PubMed ID: 18523731
[TBL] [Abstract][Full Text] [Related]
40. Folate-modified poly(2-ethyl-2-oxazoline) as hydrophilic corona in polymeric micelles for enhanced intracellular doxorubicin delivery.
Qiu LY; Yan L; Zhang L; Jin YM; Zhao QH
Int J Pharm; 2013 Nov; 456(2):315-24. PubMed ID: 24016742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
